SCHEMBL2356464

SCHEMBL2356464

CCOC(=O)c1ccc(Oc2ccc(C(=O)Nc3ccccc3C(=O)O)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.71
▸ RAB9A P51151 3/20 0.71
▸ NPC1 O15118 2/20 0.71
▸ MEN1 O00255 2/20 0.71
▸ KMT2A Q03164 2/20 0.71
▸ LMNA P02545 2/20 0.62
▸ KDM4E B2RXH2 1/20 0.62
▸ ELANE P08246 1/20 0.61
▸ PRTN3 P24158 1/20 0.61
▸ CA12 O43570 1/20 0.61
▸ CA4 P22748 1/20 0.61
▸ CA7 P43166 1/20 0.61
▸ PLK1 P53350 4/20 0.61
▸ GAA P10253 3/20 0.59
▸ ALDH1A1 P00352 2/20 0.57
▸ HPGD P15428 2/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ ABL1 P00519 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ RIN1 Q13671 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30466712 0.87 MEN1 (0.72) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL2025586 0.87 MEN1 (0.72) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL2291746 0.86 MEN1 (0.67) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL2292518 0.86 SERPINE1 (0.71) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL2289650 0.83 F10 (0.70) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL8027764 0.83 MEN1 (0.67) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL11594005 0.82 KDM4E (0.58) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL9575455 0.82 KDM4E (0.80) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL31730773 0.82 KDM4E (0.80) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL2291001 0.81 NR1H4 (0.62) SMN1; SMN2RAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 — — US claimed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 — — US claimed
JP-2008546661-A — — 2008-12-25 — — JP claimed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 — — EP claimed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 — — WO claimed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 — — US claimed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 — — US disclosed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 — — US disclosed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 — — EP disclosed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 — — WO disclosed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281810-A1 Novel anthranilic acid derivatives GPR84, HCAR1, GPR88 SMN1; SMN2 3830/4885RAB9A 1353/4885NPC1 3594/4885
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 SMN1; SMN2 3904/4885RAB9A 1445/4885NPC1 3210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback